Study variables:
Demographic variables such as age, sex, underlying oncologic or hematological disease, reception of HSCT, and development of graft-versus-host disease were recorded. PP was defined as antifungal prophylaxis using posaconazole (in oral suspension) for more than seven consecutive days in a patient without symptoms suggestive of invasive fungal infection.
Variables associated with toxicity and the effectiveness of PP were also registered, including the prophylactic dose used, concomitant use of proton pump inhibitors, presence of mucositis, clinical manifestations (while using PP), liver enzyme values - alanine-aminotransferase (ALT) and aspartate aminotransferase (AST)- and the history and development of new fungal infection during antifungal prophylaxis (breakthrough fungal infection). Liver function test values ​​were divided into 3 periods: before (AST and ALT tests obtained 2 weeks before the initiation of PP); during (maximum AST and ALT values during PP); and after PP (AST and ALT tests performed up to 2 weeks after discontinuing PP). To determine and classify invasive fungal infections as possible, probable, and proven, the diagnostic criteria of the European Organization for Research and Treatment of Cancer and Mycoses Study Group of the National Institute of Allergy and Infectious Diseases (EORTC/MSG) were used (8). No data regarding posaconazole plasma levels were collected because the test was not available at the institution during the data collection period.